Eustephia

Other Names

Amaryllis bicolorAmaryllis bicolor Ruiz & Pav.Eustephia armiferaEustephia armifera J.F.Macbr.Eustephia Cav.Eustephia coccineaEustephia coccinea Cav.Eustephia coccinea var. multifloraEustephia coccinea var. multiflora VargasEustephia darwiniiEustephia darwinii VargasEustephia hugoeiEustephia hugoei VargasEustephia kawideiEustephia kawidei VargasEustephia longibracteataEustephia macleanicaEustephia macleanica Herb.EustephieaeHippeastrum bicolorHippeastrum bicolor (Ruiz & Pav.) BakerPhaedranassa rubroviridisPhaedranassa rubroviridis BakerPhycella bicolorPhycella bicolor (Ruiz & Pav.) Herb.

Synopsis

Eustephia: Encyclopedic Reference

1. Identity: Botanical Classification, Natural Source, and Forms

Taxonomic Identity

Eustephia is a genus of South American plants in the Amaryllis family (Amaryllidaceae). All six known species are native to Peru, with the range of one species extending also into Bolivia. Under the APG IV classification, the full hierarchy places it in the domain Eukaryota, kingdom Plantae, order Asparagales, family Amaryllidaceae, subfamily Amaryllidoideae, and tribe Eustephieae.

The genus was formally published by the Spanish botanist Antonio José Cavanilles in 1795, with Eustephia coccinea Cav. as the type species. The tribe Eustephieae itself was resurrected from the Stenomesseae in 1995 by Meerow.

Eustephieae is positioned within subfamily Amaryllidoideae as a sister group to the remainder of the tetraploid Andean clade. The tribe contains four genera: Eustephia, Chlidanthus, Hieronymiella, and Pyrolirion. The Eustephieae form the southern limit of the Andean clade and are found in Peru in the southern Andes, and the northern Andes of Argentina, Bolivia, and Chile.

Within the tribe, Eustephia is distinguished morphologically in that its staminal corona is reduced to basal connation, but with acute appendages distally on both sides of the primarily filiform filaments. DNA sequencing has confirmed that the genus is a member of the Eustephieae tribe, sister to Chlidanthus, Hieronymiella, and Pyrolirion.

Accepted Species

The accepted species of Eustephia include: E. armifera, E. coccinea, E. darwinii, E. hugoei, E. kawidei, and E. longibracteata. Eustephia (6 species) is endemic to Peru; notably, Chlidanthus is distributed from Peru to Bolivia, Pyrolirion (6 species) from Peru to northern Chile, and Hieronymiella (8 species) ranges from southern Bolivia to northwestern Argentina.

Morphological Characteristics

Eustephia are bulbous plants with linear leaves. The pendent to declinate, tubular flowers display green colouration towards the tip. All six known species are native to Peru, with the range of one species extending also into Bolivia. The chromosome count is 2n = 46. The bulbs are summer-growing and dormant in winter, and can be grown like a hybrid Hippeastrum, keeping them relatively dry in winter. The flowers are tubular, pink to red with green tips to the tepals, somewhat resembling the flower of a Phaedranassa.

Habitat

These plants are typically found in rupicolous and saxicolous habitats along the eastern Andean slopes, especially in upper inter-Andean valleys with seasonally dry to subhumid shrub–herb vegetation. Eustephia is a small genus with 6 species in the family Amaryllidaceae from southern Peru to Bolivia, where they grow in high altitude subtropical forests.

Common Forms and Preparations

Because Eustephia is a genus of limited commercial development and is primarily the subject of recent academic phytochemical research rather than a widely commercialized supplement, there are no established standardized finished-product forms on the market documented in authoritative sources. Research studies have used alkaloid-enriched extracts (AEEs) obtained from bulbs and leaves, prepared with organic solvents such as methanol and ethanol. The study focused on the alkaloid profiles and pharmacological potential of bulb and leaves extracts from three Peruvian Eustephia species (E. coccinea, E. darwinii, and E. hugoei). In traditional Andean practice, the plant material has been used in oral and topical preparations (discussed in detail in Section 2 below).

2. Traditional and Historical Use

Andean Cultural Context

In Peru, the Inca people frequently depicted flowers of Amaryllidaceae (including Ismene, Pyrolirion, and Stenomesson) on ceremonial drinking vessels, reflecting the deep cultural integration of this plant family in Andean civilization. Eustephia species, as members of the same family and ecologically co-distributed in the Andean highlands, exist within this broader tradition of Amaryllidaceae use. Northern Peru represents the "health axis" of the old Central Andean cultural area stretching from Ecuador to Bolivia, and the traditional use of medicinal plants in this region possibly dates back as far as the first millennium B.C.

Recorded Traditional Uses of Eustephia coccinea

Eustephia coccinea ethanolic extract was traditionally employed in the treatment of inflammatory conditions. Despite the cultural and ecological relevance of the genus, scientific studies into Eustephia have remained limited.

Ethnobotanical surveys in Northern Peru have documented Eustephia coccinea as a plant used in traditional medicine. Its recorded uses include treatment of arthritis and rheumatism (oral administration of dried bark material), stomach inflammation (topical application), and wound care. The plant has also been documented in the context of traditional Peruvian healers' pharmacopoeia for kidney inflammation.

Little is known about the use of Amaryllidaceae plants in the treatment of fungal infections, and the mention of Eustephia coccinea specifically for such purposes in the Andean Peru region is considered symbolically significant within the ethnobotanical literature.

Broader Amaryllidaceae Traditional Medicine Context

Members of the Amaryllidaceae family are renowned for their appealing floral attributes, their biologically relevant alkaloid principles, as well as their notable presence in traditional medicine (TM) structures. This plant family is one of the most popular bulbous plant families used in alternative approaches to diseases. There has been significant interest in the Amaryllidaceae as a source of anti-inflammatory substances, and their usage for inflammatory conditions is most prominent, with substantive evidence emerging from several locations around the world.

Huge numbers of Amaryllidaceae plants are traded for traditional medicines. Africans have used the bulbs and leaves as poultices and decoctions for treating sores and digestive disorders, though in large dosages they are extremely poisonous. While this describes African Amaryllidaceae more broadly, it illustrates the general pattern of bulb-based traditional preparations common across the family.

3. Key Constituents and Active Compounds

The Amaryllidaceae Alkaloid Framework

The Amaryllidaceae family represents a prolific source of pharmacologically active compounds, boasting over 700 diverse alkaloids identified to date. These alkaloids are classified into nine subgroups related to leading compounds: lycorine, norbelladine, homolycorine, crinine, haemanthamine, narciclasine, tazettine, montanine, and galanthamine. Amaryllidaceae alkaloids are biosynthesized from tyramine and 3,4-dihydroxybenzaldehyde, derived from the amino acids tyrosine and phenylalanine, respectively.

Alkaloid Profile Specific to Eustephia

Twenty-six alkaloids were identified in the alkaloid-enriched extracts (AEEs) prepared from Eustephia species. Alkaloid profiling was conducted on alkaloid-enriched extracts (AEEs) obtained from both the bulbs and leaves of three Eustephia species: E. coccinea (from three locations), E. hugoei, and E. darwinii. GC-MS analysis revealed the presence of approximately sixty-three alkaloids in the analyzed samples, twenty-six of which were successfully identified; components contributing less than 5% of the total ion current (TIC) were excluded. UPLC-MS/MS analysis of bulb samples provided complementary structural information.

Homolycorine-type alkaloids predominated across the overall alkaloid profile, followed by unidentified compounds and lycorine-type alkaloids.

Species-Level Chemical Differentiation

Homolycorine-type alkaloids predominated in E. darwinii and E. hugoei, whereas E. coccinea displayed greater chemical diversity, with assoanine as the main detected alkaloid. In addition, candimine was widely distributed across all three species.

The observed chemotypic diversity in Eustephia species reflects a complex interplay of genetic, environmental, geographical, and developmental factors. The recurrent presence of unidentified compounds contributing significantly to the relative abundance across multiple Eustephia alkaloid extracts reinforces the value of these plants as promising sources of potentially novel alkaloids.

Phenolic and Flavonoid Constituents

The phenolic and flavonoid levels as well as the antioxidant activity of the methanolic extracts were also determined in the landmark 2025 phytochemical study. These non-alkaloidal constituents contribute to the overall antioxidant profile of the plant, although they have not yet been individually characterized for Eustephia in published primary literature.

Pharmacologically Relevant Alkaloids Across the Family

The Amaryllidaceae family, particularly the subfamily Amaryllidoideae, is notable for producing a unique and diverse range of alkaloids, many of which display pharmacological properties including anticancer, antiviral, antibacterial, anti-inflammatory effects, and the inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). Among them, galanthamine has been clinically approved for the palliative treatment of Alzheimer's disease.

Chemically, the Amaryllidaceae is known for its unique alkaloid constituents, which are divisible into six structurally diverse groups, all related as a consequence of their biogenesis from the common amino acid–derived precursor norbelladine. The alkaloid candimine, detected across all studied Eustephia species, has been of particular interest. Multiple alkaloids derived from the Amaryllidaceae family have demonstrated potent in vitro trypanocidal activity, notably candimine and hippeastrine, which exhibit selective efficacy against the intracellular amastigote form.

4. Mechanisms of Action

Cholinesterase Inhibition

Amaryllidaceae alkaloids are known to exert an array of physiological effects including AChE inhibitory activity. In the context of Eustephia specifically, the alkaloid-enriched extracts (AEEs) showed stronger enzyme inhibition of acetylcholinesterase (AChE) compared to butyrylcholinesterase (BuChE).

The structural basis for cholinesterase inhibition by Amaryllidaceae alkaloids is well described in the broader family literature. A structure–activity relationship (SAR) analysis and molecular docking studies indicated that effective acetylcholinesterase (AChE) inhibition requires interactions with key active site residues, Trp286 and Tyr337. The most important application in medicine of Amaryllidaceae alkaloids is represented by the use of galanthamine to treat Alzheimer's disease; galanthamine is able to selectively inhibit the enzyme acetylcholinesterase (AChE), which plays a fundamental role in the disease.

Antiparasitic Mechanisms

The in vitro anti-trypanosomal activity demonstrated by Eustephia alkaloid-enriched extracts is attributed to the alkaloid candimine and related compounds. Candimine and hippeastrine have demonstrated potent in vitro trypanocidal activity, exhibiting selective efficacy against the intracellular amastigote form of Trypanosoma cruzi. These findings underscore the therapeutic potential of Amaryllidaceae alkaloids as promising leads in the development of novel antiparasitic agents.

Anti-Inflammatory Mechanisms

Lycorine and narciclasine have displayed potent effects against pain, swelling, asthma, and arthritis in a recent review summarizing 140 anti-inflammatory principles from Amaryllidaceae plants. The anti-inflammatory use of E. coccinea in traditional Andean medicine is consistent with the known mechanisms of the Amaryllidaceae alkaloid class to which its constituents belong.

Antioxidant Activity

Methanolic extracts of Eustephia were assessed for antioxidant activity in the 2025 study. By characterizing alkaloid profiles, quantifying total phenolics and flavonoids, and evaluating antioxidant activity, cholinesterase inhibition, and in vitro anti-T. cruzi effects, that work identified promising bioactive compounds with potential applications in the treatment of neurodegenerative and parasitic diseases.

5. Scientific Evidence by Area of Use

5.1 Cholinesterase Inhibition and Potential Relevance to Neurodegenerative Disease

Study type and population: In vitro enzyme inhibition assay using alkaloid-enriched extracts (AEEs) from bulbs and leaves of E. coccinea, E. darwinii, and E. hugoei, published in November 2025 in the peer-reviewed journal Plants (MDPI/PMC, DOI: 10.3390/plants14223510).

The inhibitory activities of AChE and BuChE were evaluated for alkaloid-enriched extracts from all three Eustephia species. The results were expressed as IC50 values. All tested samples exhibited AChE inhibitory activity, with greater potency compared to BuChE. The bulb extract of E. coccinea from Pisac (EB2) showed the strongest AChE inhibition (IC50 of 2.89 μg/mL), while the bulb extracts of E. coccinea (Taray), E. darwinii, and E. hugoei also displayed notable AChE activity (IC50 values below 10 μg/mL).

The AEE from E. coccinea leaves showed the highest AChE inhibition overall (IC50 = 1.82 μg/mL), while the AEE from bulbs exhibited the strongest BuChE inhibitory activity (IC50 = 61.22 μg/mL).

Evidence strength: All results are from in vitro (cell-free enzyme assay) experiments only. Despite their cultural and ecological relevance, scientific studies into Eustephia remain limited. There are no animal model data or human clinical trials of any Eustephia extract for cognitive outcomes. The evidence for cholinesterase inhibition is preliminary and strictly preclinical.

5.2 Anti-Trypanosoma cruzi (Chagas Disease) Activity

Study type and population: In vitro antiparasitic assay using AEEs from bulbs and leaves of E. coccinea, E. darwinii, and E. hugoei, testing activity against both epimastigote and amastigote forms of Trypanosoma cruzi; published in Plants (MDPI/PMC, 2025).

Regarding anti-T. cruzi effect, the E. darwinii bulbs AEE was most potent and selective against amastigote forms (IC50 = 2.1 μg/mL; selectivity index [SI] = 8.83). Leaf extracts exhibited weak activity, requiring higher concentrations to inhibit parasite growth.

Chagas disease, caused by Trypanosoma cruzi, affects over 7 million people globally, mainly in Latin America. While traditionally spread by insect vectors in rural areas, urban migration has shifted the risk to cities, even where transmission is no longer active. Chagas disease now spreads through non-vector routes like congenital transmission, blood transfusions, and organ transplants. Despite its global reach, treatment remains limited and available drugs (benznidazole and nifurtimox) are toxic, less effective in chronic cases, and often inaccessible.

These findings underscore the potential of Peruvian Eustephia species as promising sources of pharmacologically relevant alkaloids, with possible applications in neurodegenerative disorders and Chagas disease.

Evidence strength: Strictly in vitro. No animal or human studies have been conducted on Eustephia extracts for Chagas disease. The selectivity index of 8.83 for E. darwinii bulbs is considered a reasonable threshold for advancing compounds to further study, but this remains extremely early-stage research.

5.3 Antibacterial Activity

Only E. coccinea ethanolic extract (traditionally employed in the treatment of inflammatory conditions) was reported as active against Staphylococcus aureus. This finding was documented in the context of Northern Peruvian ethnobotanical antibacterial screening studies, which tested extracts of 171 plant species against Staphylococcus aureus and Escherichia coli using disc diffusion bioassays. These species did not produce particularly high inhibition rates in any case, and were not the first choice of healers when trying to find remedies for bacterial infections.

Evidence strength: In vitro disc diffusion data only, from a survey-type ethnopharmacological screen. Results were at low levels of inhibition. No mechanistic, animal, or clinical studies have been published specifically on Eustephia's antibacterial properties.

5.4 Antioxidant Activity

Antioxidant activity of methanolic extracts of Eustephia species was measured as part of the 2025 phytochemical profiling study alongside alkaloid quantification and antiparasitic assays. The phenolic and flavonoid levels as well as the antioxidant activity of the methanolic extracts were determined. Specific IC50 or DPPH values for Eustephia's antioxidant activity have not been reported in isolation in the accessible primary literature at the level of detail needed for comparison.

Evidence strength: Antioxidant data exist in vitro as part of a broader characterization study. No human clinical evidence for antioxidant health outcomes exists.

5.5 Anti-Inflammatory Use (Traditional, with Limited Experimental Support)

Fifty-one species from the Amaryllidaceae family have been identified for their traditional use in treating inflammation across 32 countries. Eustephia coccinea is among the Amaryllidaceae used in the Andean Peru region for inflammatory conditions. The 2025 study confirmed the chemical plausibility of these uses by identifying alkaloid classes (lycorine-type, homolycorine-type) that are known, in the broader Amaryllidaceae literature, to have anti-inflammatory properties.

Lycorine and narciclasine have displayed potent effects against pain, swelling, asthma, and arthritis in a recent review summarizing 140 anti-inflammatory principles from Amaryllidaceae plants.

Evidence strength: Traditional use in Peru is documented ethnographically. The anti-inflammatory activity of related alkaloid classes in the broader Amaryllidaceae family is supported by in vitro and some in vivo data. There are no clinical trials, and no controlled human data specific to Eustephia for anti-inflammatory outcomes.

6. Body Systems and Health Areas of Association

Nervous system / Neurodegeneration: AChE and BuChE inhibitory activity of Eustephia alkaloid extracts, particularly relevant to the cholinergic hypothesis of Alzheimer's disease, based on in vitro data.
Infectious disease / Parasitic disease: Demonstrated in vitro activity against Trypanosoma cruzi, the causative agent of Chagas disease, with the most potent results from E. darwinii bulb extracts.
Immune and inflammatory system: Traditional Andean use for arthritis, rheumatism, and general inflammation; the family-level alkaloid literature provides mechanistic plausibility.
Musculoskeletal system: Traditional use for arthritis and rheumatism documented in Northern Peruvian ethnobotanical surveys.
Gastrointestinal system: Traditional use for stomach inflammation recorded in ethnobotanical literature.
Integumentary system / Wound care: Topical traditional use for wound treatment recorded in ethnobotanical surveys.
Antimicrobial: Preliminary in vitro antibacterial activity against Staphylococcus aureus documented in survey screening.
Antioxidant: In vitro antioxidant capacity measured in methanolic extracts alongside phytochemical profiling.

7. Dosage Forms and Dosages Reported in Studies

No human clinical trials involving Eustephia have been published, and therefore no human dosage recommendations exist in the peer-reviewed literature. The following reflects only what has been reported in laboratory research:

Alkaloid-Enriched Extracts (AEEs): Alkaloid profiling was conducted on alkaloid-enriched extracts (AEEs) obtained from both the bulbs and leaves of three Eustephia species. AEEs were the primary test material in the 2025 pharmacological study.
Cholinesterase inhibition (in vitro IC50 values): The AEE from E. coccinea leaves showed the highest AChE inhibition (IC50 = 1.82 μg/mL), while the AEE from bulbs exhibited the strongest BuChE inhibitory activity (IC50 = 61.22 μg/mL).
Anti-T. cruzi activity (in vitro IC50 values): The E. darwinii bulbs AEE was most potent against amastigote forms (IC50 = 2.1 μg/mL; SI = 8.83).
Methanolic extracts: Used for determination of phenolic and flavonoid content and antioxidant activity, though specific concentrations used in assays have not been separately reported in the accessible literature excerpts.

No standardized supplement dose has been established or validated in any regulatory, pharmacopeial, or clinical context for any Eustephia species.

8. Safety Considerations

General Amaryllidaceae Toxicity Profile

Ingestions of plant material from Amaryllidaceae, especially the bulbs of daffodils, are known to be toxic, representing a persistent cause of poisoning in humans and animals. Amaryllidaceae plants synthesize poisons such as lycorine and galanthamine, and this toxicity should always be considered.

Lycorine: The Primary Emetic/Toxic Alkaloid of the Family

Ingestions of plant material from Amaryllidaceae are known to be toxic, representing a persistent cause of poisoning in humans and animals. Empiric data from case reports have suggested that the alkaloid lycorine could be the toxic constituent of the multi-component mixture responsible for symptoms like nausea and emesis.

In a controlled animal study, researchers studied the dose–effect relationship of lycorine-induced nausea and emesis and the toxicokinetics of lycorine in beagle dogs. Subcutaneously administered lycorine induced nausea and emesis starting at 0.5 mg/kg body weight, reaching statistical significance at 1.0 mg/kg. The maximum emetic dose (ED100) was 2 mg/kg body weight. The results provide evidence that lycorine can be considered a main, if not the crucial, constituent responsible for nausea and emesis in human and animals in poisoning due to ingestion of plant material of the Amaryllidaceae.

Whether Eustephia species contain lycorine at significant concentrations has not been definitively established in the literature reviewed; the dominant alkaloid class identified in the 2025 study was the homolycorine type (in E. darwinii and E. hugoei), with assoanine as the primary alkaloid in E. coccinea.

Bulb Toxicity: A Consistent Pattern Across the Family

Huge numbers of Amaryllidaceae plants are traded for traditional medicines, but the bulbs and leaves used as poultices and decoctions are extremely poisonous in large dosages. This is particularly relevant to Eustephia, given that most phytochemical work has focused specifically on bulb extracts.

Cytotoxic Potential of Alkaloid Classes Present

There have been sustained projections for the emergence of an anticancer agent related to pancratistatin due to the potency, selectivity, low toxicity and high tolerability of this alkaloid series. The lycorine series of alkaloids have garnered widespread interest as cytotoxic agents and were amongst the earliest of the Amaryllidaceae constituents to exhibit such activity. Cytotoxic activity of alkaloid classes found in Eustephia (lycorine-type and homolycorine-type) implies that concentrated extracts may have cytotoxic potential, though this has not been directly tested for Eustephia-derived material in published studies.

Absence of Human Safety Data

The genus Eustephia remains largely unexplored. Despite cultural and ecological relevance, scientific studies into Eustephia remain limited. No human pharmacokinetic data, clinical safety studies, or formal toxicological assessments of any Eustephia extract have been published. The selectivity index (SI) values reported in the 2025 study for anti-T. cruzi activity provide a preliminary indication of differential cytotoxicity between parasitic cells and host cells, but do not constitute human safety data.

Regulatory Status

Eustephia is not listed in any major regulatory pharmacopoeia (USP, European Pharmacopoeia, WHO monographs, ESCOP, or German Commission E monographs) and is not recognized by the NIH Office of Dietary Supplements or NCCIH as a supplement with an established evidence base. It does not appear in the NIH ODS list of botanical supplement fact sheets. There is no established acceptable daily intake (ADI) or tolerable upper limit (UL) for any Eustephia preparation from any regulatory body.

9. Research Gaps and Current Status

The 2025 study represents the first comprehensive research into the phytochemical composition and pharmacological potential of Eustephia species, specifically E. coccinea, E. darwinii, and E. hugoei, native from the southern Peruvian Andes.

Key gaps in the current scientific literature on Eustephia include: the absence of any human or animal in vivo pharmacological or safety studies; no isolation and characterization of individual pure compounds from Eustephia (all pharmacological results are from mixed alkaloid-enriched extracts); no pharmacokinetic data; no dose-ranging or toxicological studies; and no clinical trials of any description. The 2025 publication constitutes substantially the entire body of controlled scientific pharmacological investigation of the genus. The ethnobotanical record documents traditional use in Peru but does not constitute proof of efficacy or safety for modern supplementation purposes.

The existing findings underscore the potential of Peruvian Eustephia species as promising sources of pharmacologically relevant alkaloids, with possible applications in neurodegenerative disorders and Chagas disease — but this potential remains, at present, entirely at the preclinical stage.

References

Health Conditions

Health conditions that Eustephia may help support.

No conditions available.

Body Systems

Body systems that Eustephia may help support.

No body systems available.